Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells

Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.

The major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.

Study Overview

• Status: Recruiting
• Conditions: Pregnant, Healthy Females; Healthy Male Newborns

Detailed Description

The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.

The clinical grade donated feeders used in this project were developed under GMP conditions using animal-free reagents. For potential future clinical applications, the iPS cells will be developed under GMP conditions, using reagents and methods that will be acceptable for clinical applications.

• Study Type: Observational
• Enrollment (Estimated): 1

Contacts and Locations

• Study Contact: Name: Benjamin E Reubinoff, MD PhD; Phone Number: 011-972-2-6774569; Email: benjaminr@ekmd.huji.ac.il
• Study Contact Backup: Name: Shelly E. Tannenbaum, MSQA; Phone Number: 011-972-2-572-2000; Email: stannenbaum@hadassah.org.il

Study Locations

• Israel
  • Jerusalem, Israel, 9112100
    • Recruiting
    • Hadassah Ein Kerem
    • Contact: Benjamin E Reubinoff, Professor; Phone Number: 972-2-6776424/5; Email: benr@hadassah.org.il
    • Contact: Shelly E Tannenbaum, MSQA; Phone Number: 972-2-6775700; Email: stannenbaum@hadassah.org.il

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

pregnant, healthy females older than 18 who signed an informed consent for the termination of the pregnancy.

pregnant healthy couples older than 18 who signed an informed consent for a c-section.

healthy male newborns, undergoing surgical circumcision who's parents older than 18 signed an informed consent.

Description

Inclusion Criteria:

• healthy, older than 18

Exclusion Criteria:

• non healthy, younger than 18

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Pre-existing Fibroblast MCB; Pre-existing fibroblast donors for hESC derivation project

Collaborators and Investigators

• Sponsor: Hadassah Medical Organization
• Investigators: Principal Investigator: Benjamin E Reubinoff, MD PhD, Chairman of Department of Obstetrics & Gynecology/IVF, Hadassah Ein Kerem

Publications and helpful links

General Publications

• Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 Nov 30;131(5):861-72. doi: 10.1016/j.cell.2007.11.019.

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2008
• Primary Completion (Estimated): December 1, 2030
• Study Completion (Estimated): December 1, 2030

Study Registration Dates

• First Submitted: December 2, 2008
• First Submitted That Met QC Criteria: December 2, 2008
• First Posted (Estimated): December 3, 2008

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 17, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: umbilical cord; termination of pregnancy; surgical circumcision
• Other Study ID Numbers: 0522-08- HMO-CTIL